On the fly News and insights, exclusive to thefly.com

MCRB

Seres Therapeutics

$7.31 /

-0.625 (-7.88%)

, SAM

Boston Beer

$728.38 /

-226.115 (-23.69%)

09:55
07/23/21
07/23
09:55
07/23/21
09:55

Fly Intel: Top five analyst downgrades

Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Seres Therapeutics (MCRB) downgraded to Sell from Neutral at Goldman Sachs with analyst Chris Shibutani saying "disappointing" top line results for the company's SER-287 Phase 2b ECO-RESET study prompts the analyst to remove projections for the asset from the model. 2. Boston Beer (SAM) downgraded to Neutral from Buy at Goldman Sachs with analyst Bonnie Herzog saying the analyst is "very surprised by the magnitude of this quarter's miss," which she says came in well below expectations despite management's "consistently confident tone" as recently as May 18. 3. Domino's Pizza (DPZ) downgraded to Neutral from Overweight at JPMorgan with analyst John Ivankoe citing valuation for the downgrade, saying the current share price is "just too high." 4. Open Lending (LPRO) downgraded to Neutral from Buy at Goldman Sachs with analyst Matthew O'Neill citing valuation for the following the stock's recent outperformance. 5. Adverum Biotechnologies (ADVM) downgraded to Neutral from Buy at Goldman Sachs with analyst Graig Suvannavejh saying the news of additional cases of hypotony "comes as a disappointment," but the formal discontinuation of the company's efforts to further expand the potential utility of ADVM-022 beyond the initial wet AMD indication and into DME "does not come as a surprise" given that he previously removed a potential revenue contribution from the DME indication on the initial news of the SUSAR. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

MCRB

Seres Therapeutics

$7.31 /

-0.625 (-7.88%)

SAM

Boston Beer

$728.38 /

-226.115 (-23.69%)

DPZ

Domino's Pizza

$530.17 /

-8.56 (-1.59%)

LPRO

Open Lending

$38.32 /

-1.6 (-4.01%)

ADVM

Adverum Biotechnologies

$2.54 /

-0.525 (-17.13%)

  • 10

    Aug

  • 16

    Aug

  • 01

    Dec

  • 13

    Aug

  • 13

    Aug

  • 10

    Dec

  • 01

    Apr

MCRB Seres Therapeutics
$7.31 /

-0.625 (-7.88%)

07/23/21 Oppenheimer
Seres Therapeutics price target lowered to $18 from $36 at Oppenheimer
07/23/21 Canaccord
Seres Therapeutics price target lowered to $29 from $42 at Canaccord
07/23/21 Chardan
Seres Therapeutics price target lowered to $16 from $30 at Chardan
07/23/21 H.C. Wainwright
Seres Therapeutics price target lowered to $25 from $46 at H.C. Wainwright
SAM Boston Beer
$728.38 /

-226.115 (-23.69%)

07/23/21 Jefferies
Boston Beer price target lowered to $685 from $760 at Jefferies
07/23/21 Morgan Stanley
Boston Beer price target lowered to $990 from $1,450 at Morgan Stanley
07/23/21 UBS
Boston Beer price target lowered to $1,080 from $1,480 at UBS
07/23/21 Deutsche Bank
Boston Beer price target lowered to $850 from $1,074 at Deutsche Bank
DPZ Domino's Pizza
$530.17 /

-8.56 (-1.59%)

07/23/21 MKM Partners
Domino's Pizza price target raised to $500 from $465 at MKM Partners
07/23/21 BMO Capital
Domino's Pizza price target raised to $500 from $410 at BMO Capital
07/23/21 Baird
Domino's Pizza price target raised to $560 from $510 at Baird
07/23/21 Oppenheimer
Domino's Pizza price target raised to $585 from $450 at Oppenheimer
LPRO Open Lending
$38.32 /

-1.6 (-4.01%)

07/23/21 Goldman Sachs
Open Lending downgraded to Neutral from Buy at Goldman Sachs
06/28/21 Canaccord
Open Lending price target raised to $55 from $45 at Canaccord
04/29/21 Stephens
AerCap named a Best Idea at Stephens
04/21/21 B. Riley
Open Lending price target raised to $38 from $30 at B. Riley
ADVM Adverum Biotechnologies
$2.54 /

-0.525 (-17.13%)

07/23/21 Goldman Sachs
Adverum Biotechnologies downgraded to Neutral from Buy at Goldman Sachs
07/23/21 SVB Leerink
Adverum Biotechnologies price target lowered to $2 from $5
07/23/21 Chardan
Adverum Biotechnologies price target lowered to $3 from $5 at Chardan
07/23/21 Cantor Fitzgerald
Adverum Biotechnologies downgraded to Neutral from Overweight at Cantor Fitzgerald

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.